Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 4/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.53 |
| ▸ | CETP | P11597 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8725921 | 1.00 | TSHR (0.62) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL6030731 | 0.82 | TSHR (0.88) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL29619605 | 0.82 | TSHR (0.55) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL1101314 | 0.82 | TSHR (0.67) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL2517900 | 0.80 | TSHR (0.84) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL28543472 | 0.80 | TSHR (0.64) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| Phosphoric Acid SCHEMBL412030 | 0.79 | TSHR (0.61) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL11775231 | 0.78 | TSHR (0.62) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL20626773 | 0.78 | TSHR (0.62) | TSHRPOLBCYP2D6ANPEPERAP1 | |
| SCHEMBL28103039 | 0.78 | TSHR (0.62) | TSHRPOLBCYP2D6ANPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2772088-B2 | — | — | 1998-07-02 | — | — | JP | claimed |
| EP-0413762-A4 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | — | 1992-01-15 | — | — | EP | claimed |
| EP-0413762-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INCORPORATED (US) | 1991-02-27 | — | — | EP | claimed |
| WO-1989010961-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INC. (US) | 1989-11-16 | — | — | WO | claimed |
| US-7521469-B2 | Phosphinic amino acid compounds | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | LES LABORATOIRES SERVER (FR) | 2008-06-26 | — | — | US | disclosed |
| US-5500414-A | TREATMENT OF PERIODONTAL DISESASE, INHIBITION OF ZINC METALLOPROTEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1996-03-19 | — | — | US | disclosed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | NPR1, NPPA, AADAT | TSHR 1322/4885POLB 2560/4885CYP2D6 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.